Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
86 participants
INTERVENTIONAL
2026-01-30
2027-09-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors
NCT02515487
Cancer and Disorders of Cognitive Functions and Quality of Life: "Cognitive Rehabilitation in Patients Suffering From Cancer and Treated With Chemotherapy"
NCT01788618
Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon
NCT01333735
Predisposing Factors Associated With Chemotherapy Toxicity in Elderly Cancer Patients
NCT02317757
Improve Cancer-related Cognitive Impairment
NCT05864274
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Prehabilitation, which involves exercise and nutritional support before treatment, has demonstrated significant benefits in the surgical setting by improving cardiorespiratory fitness, physical function, and recovery. However, its role before chemotherapy is less clear. Exercise promotes both physical and brain health by increasing growth factors, improving blood flow to the brain, and supporting the formation of new brain cells and blood vessels.
This study aims to investigate whether an exercise-based prehabilitation programme can reduce the symptoms of chemo-brain, improve brain health and enhance quality of life in older adults undergoing chemotherapy for colorectal cancer. Participants aged 60-85 years with stage II or III colorectal cancer scheduled to receive chemotherapy (fluorouracil, capecitabine, or oxaliplatin) are eligible. Suitability to receive chemotherapy must be confirmed by the clinical care team via medical records.
Participants will take part in a remotely supervised exercise programme before and during chemotherapy. The programme consists of four 40-minute sessions per week, including two supervised sessions delivered via video by the lead investigator and two independent sessions supported by an exercise booklet and videos.
Each session includes a warm-up, 20 minutes of aerobic exercise at around 60% of peak fitness, strengthening exercises for upper and lower limbs using resistance bands, and a cool-down. Exercises will be adjusted based on individual ability, with progressions and regressions provided. Participants must have a family member, carer, or friend present during supervised sessions for safety. Psychological support and multivitamin supplementation will also be included.
Assessments will take place at three time points:
* Visit 1 (baseline): 3-4 weeks before chemotherapy.
* Visit 2: Within 72 hours of starting chemotherapy.
* Visit 3: 3-4 days after the final chemotherapy session. A follow-up will occur three months after chemotherapy. At each assessment, cardiorespiratory fitness (CPET), blood samples, brain activity (EEG), cognitive tests, and quality of life questionnaires will be completed.
While there is no guarantee of direct benefit, participation may improve fitness, reduce fatigue, and enhance quality of life during chemotherapy. Exercise can also support mood, manage anxiety and depression, and potentially lessen cognitive changes linked to chemotherapy. Participants will contribute to research that could help improve future cancer care.
Risks are minimal and will be closely managed. CPET carries a small risk of cardiac events or fainting, but all tests will be conducted under medical supervision with appropriate screening, warm-ups, and safety procedures in place. Exercise carries a small risk of muscle strain, but exercises will be tailored to ability.
EEG recordings are safe, though mild skin irritation may occur from the cap or cleaning solution. Blood sampling can cause minor bruising or discomfort, but it will be performed by trained professionals. Cognitive testing may occasionally cause fatigue or frustration.
All procedures will take place in hospital settings with immediate access to medical staff. Any clinical concerns identified during testing will be reported to the participant's oncology team or helpline, following consent procedures. The study will not alter or interfere with normal clinical care.
All data, including personal contact information, will be securely managed within Lancaster University's Microsoft Teams environment, ensuring full GDPR compliance. The study is run by Lancaster University in collaboration with East Lancashire Teaching Hospitals NHS Trust, Lancashire Teaching Hospital NHS Trust, and University Hospitals of Morecambe Bay NHS Trust. Recruitment and testing will take place across all participating sites.
The study is due to begin in early 2026 and will run until September 2027. This study is funded by North West Cancer Research.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prehabilitation group
This group will receive the exercise programme before and during chemotherapy (4 times per week; 2 supervised online home-based sessions and 2 unsupervised home-based sessions), with the addition of daily multivitamins and behavioural support via a weekly telephone check-up.
Exercise Prehabilitation
The prehabilitation group will be asked to undertake a remote exercise programme. The home-based exercise sessions will take place four times per week. Two will be unsupervised exercise sessions, and the other two will be online supervised exercise sessions. Each session will last for approximately 40 minutes for a minimum of 3 weeks, a maximum of 4 weeks. Exercise tolerance will be built up from 2 supervised sessions (week 1) up to the recommended four sessions per week (week 3/4). The number of sessions will be sustained throughout chemotherapy until the end of chemotherapy (visit 3).
The participants will be remotely supervised by a qualified exercise instructor. They will have a combination of aerobic and resistance exercise within each session. It will be individualised and tailored to their physical abilities. The exercises will target their upper body (arms and shoulders) and legs. Exercise programmes, videos, and links to supervised sessions will be provided.
Multivitamins
Multivitamins will be given following the first testing visit until the third visit (following the last chemotherapy round). The multivitamins will be taken daily before and during chemotherapy. The multivitamin supplement contains a combination of 24 essential vitamins (vitamin A, D2, B1, B2, B6, B12, C, E, Biotin, nicotinamide, pantothenic acid and folic acid), minerals and trace elements (calcium, iron, copper, phosphorus, magnesium, potassium, zinc, iodine, manganese, selenium, chromium, and molybdenum). Each multivitamin and mineral plays a vital role in the efficient daily maintenance of many body processes.
Standard Care (in control arm)
Participants with colorectal cancer will receive chemotherapy treatment.
Standard Care Group
This group will receive their treatment as planned as part of standard care, but will not receive the prehabilitation (exercise, nutrition, and behavioural support).
Standard Care (in control arm)
Participants with colorectal cancer will receive chemotherapy treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise Prehabilitation
The prehabilitation group will be asked to undertake a remote exercise programme. The home-based exercise sessions will take place four times per week. Two will be unsupervised exercise sessions, and the other two will be online supervised exercise sessions. Each session will last for approximately 40 minutes for a minimum of 3 weeks, a maximum of 4 weeks. Exercise tolerance will be built up from 2 supervised sessions (week 1) up to the recommended four sessions per week (week 3/4). The number of sessions will be sustained throughout chemotherapy until the end of chemotherapy (visit 3).
The participants will be remotely supervised by a qualified exercise instructor. They will have a combination of aerobic and resistance exercise within each session. It will be individualised and tailored to their physical abilities. The exercises will target their upper body (arms and shoulders) and legs. Exercise programmes, videos, and links to supervised sessions will be provided.
Multivitamins
Multivitamins will be given following the first testing visit until the third visit (following the last chemotherapy round). The multivitamins will be taken daily before and during chemotherapy. The multivitamin supplement contains a combination of 24 essential vitamins (vitamin A, D2, B1, B2, B6, B12, C, E, Biotin, nicotinamide, pantothenic acid and folic acid), minerals and trace elements (calcium, iron, copper, phosphorus, magnesium, potassium, zinc, iodine, manganese, selenium, chromium, and molybdenum). Each multivitamin and mineral plays a vital role in the efficient daily maintenance of many body processes.
Standard Care (in control arm)
Participants with colorectal cancer will receive chemotherapy treatment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 60-85 years old.
* Fluent in English
* Male and female participants
* Not engaged in structured exercise training\* within the six months before providing consent.
Exclusion Criteria
* Current musculoskeletal injury or physical limitations that prevent completion of cardiopulmonary exercise testing (CPET).
* Any contraindication to the multivitamin supplementation (Forceval), including known hypercalcaemia, haemochromatosis, peanut or soya allergy, current use of phenytoin or tetracycline antibiotics, and clinically significant impaired renal or hepatic function.
* Evidence of pre-existing cognitive impairment, including diagnosis of dementia, other neurodegenerative disorders (e.g., Alzheimer's disease), or clinically indicated mild cognitive impairment.
* Diagnosis of atrial fibrillation and haematological malignancy.
* Participants without home internet access will be excluded due to the online delivery of the exercise programme.
* Diagnosis of profound hearing loss.
* Receiving palliative care.
* Presence of synchronous cancer.
* Structured exercise refers to planned and organised physical activity, such as gym workouts, exercise classes or a team sport, which are designed to improve or maintain physical fitness, often with instruction, rules, and goals.
60 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. Chris Gaffney
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Chris Gaffney
Senior Lecturer in Integrative Physiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
East Lancashire Teaching Hospitals NHS Trust
Blackburn, Lancashire, United Kingdom
University Hospitals Morecambe Bay Trust, Royal Lancaster Infirmary
Lancaster, Lancashire, United Kingdom
Lancashire Teaching Hospitals NHS Trust
Preston, Lancashire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Christopher Gaffney, BSc (Hons.) MSc PhD FHEA
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AR2024.07
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
25/EM/0250
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.